Novan Inc (NOVN) Stock
NOVN is no longer traded. Novan was delisted from the Nasdaq in September 2023.
Prices on this page are historical; the last trade was September 26, 2023 at $0.03.
Novan stock price history
NOVN final trading statistics
- Final close
- $0.03
- Final trading day
- Sep 26, 2023
- Market cap at delisting
- $2.64M
- Shares outstanding
- 28.02M
- Final 52-week range
- $0.02 – $2.15
- Avg. volume (final 3 mo.)
- 1,044,900
- All-time high (split-adj.)
- $290.60 · Dec 2016
- All-time low (split-adj.)
- $0.02 · Sep 2023
- Return since IPO
- -100.0%
- Beta
- -0.04
- Book value / share
- -$0.10
- Price / book
- -0.34
Novan annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $23.61M | -$19.6M | -$1.68 |
| FY2021 | $2.82M | -$28.8M | -$1.82 |
| FY2020 | $4.21M | -$30.2M | -$3.50 |
| FY2019 | $4.48M | -$30.8M | -$11.70 |
| FY2018 | $5.99M | -$12.7M | -$6.30 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Novan Inc
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, Novan, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Novan stock FAQ
What happened to Novan stock?
Novan stock was delisted from the Nasdaq. Its final close was $0.03 on September 26, 2023.
Is NOVN stock still trading?
No. NOVN was delisted from the Nasdaq in September 2023 and no longer trades on a U.S. exchange.
What was the last price of NOVN stock?
NOVN closed at $0.03 on its final trading day, September 26, 2023, for a market value of about $2.64M.
What were Novan's revenue and earnings in its last full fiscal year?
Novan reported revenue of $23.61M and net income of -$19.6M in fiscal 2022, its last full year as a public company.
When did Novan go public?
Novan Inc stock began trading on September 21, 2016.